Biogen looks to M&A to overcome competition to its MS franchise | Fierce Pharma
Biogen Acquires Alzheimer's and Parkinson's Asset from Pfizer in $710 Million Deal | BioSpace
FAQ on FDA Approval of Aducanumab - CurePSP
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb - Pharmaceutical Processing World
Cover Layout Presentation name
Phil's Journal: My Good Friend Is the First to Receive Biogen's Alzheimer's Drug in New Trial - Being Patient
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
Biogen on Twitter: "We'll be showcasing our work in neuroscience including the areas of multiple sclerosis (#MS), spinal muscular atrophy (#SMA), Alzheimer's Disease (#AD) and progressive supranuclear palsy (#PSP) with poster and
Bristol-Myers offloads anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones | Fierce Biotech
Medscape - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6185Tn3JH | Facebook
Twitter \ Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe"
Biogen | Contract Pharma
Biogen deals the tau pipeline another blow | Evaluate
Biogen Ends Trial of Its Drug for PSP - CurePSP
Gosuranemab: another Alzheimer's candidate to bite the dust
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Biogen - Pioneers In Neuroscience
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Research | Pipeline
Biogen Discontinues Gosuranemab Trial in Progressive Supranuclear Palsy
Biogen Cancels Another Dementia Drug in Phase 2 Clinical Trial - Being Patient
Biogen 2019 Outlook (NASDAQ:BIIB) | Seeking Alpha
AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. | Barron's
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Progressive Supranuclear Palsy Treatment Market Estimated to Reach A Valuation Of US$ 20.68 Million By 2027 – with AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc.,
Biogen abandons tau antibody for Alzheimer's after phase 2 miss -
